CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

CRISPR Therapeutics AG (CRSP) recently closed down 2.46% at $74.89, underperforming the S&P 500, despite a robust 48.19% gain over the past month. Ahead of its upcoming earnings release, analysts project a quarterly EPS of -$1.32, marking a 30.69% year-over-year decline, while revenue is expected to surge 1185.5% to $7.71 million. For the full fiscal year, estimates anticipate a 51.84% EPS drop to -$6.59 and a 10.47% revenue decrease to $33.41 million, with the Zacks Consensus EPS estimate declining 0.48% over the past 30 days, resulting in a Zacks Rank #3 (Hold).

Analysis

CRISPR Therapeutics AG (CRSP) closed at $74.89, experiencing a 2.46% daily decline that notably underperformed the broader market, including the S&P 500's 0.28% loss. This recent dip, however, follows a strong monthly performance where CRSP shares appreciated by 48.19%, significantly outperforming both the Medical sector's 3.31% gain and the S&P 500's 4.03% increase over the same period.

Upcoming financial results present a mixed picture: the company's projected quarterly EPS is -$1.32, indicating a 30.69% year-over-year drop, while revenue is expected to surge by 1185.5% to $7.71 million. For the full fiscal year, Zacks Consensus Estimates forecast a 51.84% decline in EPS to -$6.59 and a 10.47% decrease in revenue to $33.41 million.

Analyst sentiment, as reflected by a 0.48% lower Zacks Consensus EPS estimate over the last 30 days, places CRSP with a Zacks Rank of #3 (Hold). Despite this, the Medical - Biomedical and Genetics industry, where CRSP operates, holds a strong Zacks Industry Rank of 96, positioning it within the top 39% of all industries.

Key Decisions for Investors

• Investors should closely monitor CRSP's upcoming earnings report to understand the drivers behind the significant projected revenue growth and the simultaneous decline in EPS.
• Consider the implications of the recent downward revision in analyst EPS estimates and the stock's Zacks Rank #3 (Hold) in light of its substantial monthly outperformance.
• Evaluate CRSP's long-term potential within the favorably ranked Medical - Biomedical and Genetics industry, while acknowledging the stock's short-term volatility and mixed financial projections.